Literature DB >> 21277204

Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes.

Kilian Conde-Frieboes1, Michael Ankersen, Jens Breinholt, Birgit Sehested Hansen, Kirsten Raun, Henning Thøgersen, Birgitte S Wulff.   

Abstract

A new class of melanocortin 4 receptor (MC4r) agonists was discovered from an unexpected sidereaction in which formaldehyde caused cyclization. These cyclophanes were found to be sub micromolar agonists of the MC1 and MC4 and were less potent on the MC3 and MC5 receptor. They were shown to compete with the peptidic antagonist SHU9119 for binding to the MC4 receptor. In an acute feeding study in Sprague Dawley rats, food intake was reduced more than 50% versus vehicle after 3 h at a dose of 1 mg/kg.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277204     DOI: 10.1016/j.bmcl.2011.01.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

Review 2.  The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options.

Authors:  L Fani; S Bak; P Delhanty; E F C van Rossum; E L T van den Akker
Journal:  Int J Obes (Lond)       Date:  2013-06-18       Impact factor: 5.095

3.  Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High-Throughput "Unbiased" Screening Campaign.

Authors:  Skye R Doering; Katie Freeman; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Travis M Lavoi; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Richard A Houghten; Mark D Ericson; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2021-04-22       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.